JPRN-UMIN000006358已完成未知
Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia - IMIDAS(Inter-Michinoku dasatinib study) 1st Line
Epidemiological and Clinical Research Information Network(ECRIN)0 个研究点目标入组 60 人开始时间: 2011年9月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Previous treatment with TKI or INF
研究者
相似试验
已完成
不适用
PhaseII study of Dasatinib in patients with chronic myeloid leukemia after Imatinib failureChronic Myeloid Leukemia (chronic phase)JPRN-UMIN000001900Inter-Michinoku Dasatinib Study(IMIDAS)60
已完成
2 期
Phase II clinical trial of dasatinib in newly diagnosed chronic phase chronic myelogenous leukemianewly diagnosed chronic myelogenous leukemia in chronic phaseJPRN-UMIN000006346Ph leukemia trial Group50
进行中（未招募）
不适用
A Phase II Study of Dasatinib (BMS-354825) in Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or Intolerant to ImatinibSubjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) who are Resistant or Intolerant to Imatinib.EUCTR2006-001279-39-BEBristol-Myers Squibb International Corporation300
进行中（未招募）
不适用
A Phase II Study of Dasatinib (BMS-354825) in Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or Intolerant to ImatinibSubjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) who are Resistant or Intolerant to Imatinib.EUCTR2006-001279-39-CZBristol-Myers Squibb International Corporation300
已完成
2 期
Dasatinib plus Chemotherapy in Philadelphia Chromosome-Positive Acute Lymphoblastic LeukaemiaACTRN12607000609459Australasian Leukaemia and Lymphoma Group (ALLG)20